SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of Bio-Reference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2016			2015			2016			2015
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics	266,012			1,848			518,534			3,857
Corporate	—			60			—			120
	$	266,012		$	1,908		$	518,534		$	3,977
Product revenues:
Pharmaceutical	$	22,807		$	22,848		$	42,706		$	38,334
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	22,807		$	22,848		$	42,706		$	38,334
Revenue from transfer of intellectual property:
Pharmaceutical	$	68,281		$	17,673		$	86,898		$	30,202
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	68,281		$	17,673		$	86,898		$	30,202
Operating income (loss):
Pharmaceutical	$	35,345		$	(4,660	)	$	34,015		$	(42,584	)
Diagnostics	10,374			(7,098		)	8,019			(15,575		)
Corporate	(17,453		)	(12,905		)	(41,286		)	(22,882		)
Less: Operating loss attributable to noncontrolling interests	—			(746		)	—			(1,281		)
	$	28,266		$	(25,409	)	$	748		$	(82,322	)
Depreciation and amortization:
Pharmaceutical	$	2,987		$	2,371		$	5,848		$	4,138
Diagnostics	21,573			1,754			40,893			3,501
Corporate	20			27			39			46
	$	24,580		$	4,152		$	46,780		$	7,685
Net income (loss) from investment in investees:
Pharmaceutical	$	391		$	(804	)	$	(4,430	)	$	(2,565	)
Diagnostics	(2,379		)	—			97			—
Corporate	—			—			—			—
	$	(1,988	)	$	(804	)	$	(4,333	)	$	(2,565	)
Revenues:
United States	$	266,044		$	2,525		$	518,482		$	5,019
Ireland	71,789			19,376			93,932			31,480
Chile	9,597			8,698			16,580			15,150
Spain	4,324			4,920			8,347			8,857
Israel	4,420			5,942			9,162			10,155
Mexico	926			968			1,635			1,852
	$	357,100		$	42,429		$	648,138		$	72,513



(In thousands)	June 30, 2016		December 31, 2015
Assets:
Pharmaceutical	$	1,283,339	$	1,234,752
Diagnostics	1,408,619		1,421,034
Corporate	82,063		143,402
	$	2,774,021	$	2,799,188
Goodwill:
Pharmaceutical	$	253,237	$	251,225
Diagnostics	437,823		492,123
Corporate	—		—
	$	691,060	$	743,348

During the three and six months ended June 30, 2015, revenue recognized under the Pfizer Transaction represented 42% of our total revenue. Refer to Note 12. During the three months ended June 30, 2016, revenue recognized under the VFMCRP Agreement represented 14% of our total revenue. No customer represented more than 10% of our consolidated revenue during six months ended June 30, 2016. As of June 30, 2016 , no customer represented more than 10% of our accounts receivable balance. As of December 31, 2015, one customer represented more than 10% of our accounts receivable balance.